A detailed history of Sjs Investment Consulting Inc. transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Sjs Investment Consulting Inc. holds 18 shares of IBRX stock, worth $80. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18
Previous 58 68.97%
Holding current value
$80
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 16, 2024

SELL
$3.32 - $6.7 $132 - $268
-40 Reduced 68.97%
18 $0
Q2 2024

Jul 16, 2024

BUY
$4.82 - $9.15 $226 - $430
47 Added 427.27%
58 $0
Q1 2024

Apr 18, 2024

BUY
$3.23 - $6.17 $35 - $67
11 New
11 $0
Q1 2023

Apr 20, 2023

SELL
$1.35 - $4.78 $1 - $4
-1 Reduced 25.0%
3 $0
Q4 2022

Jan 23, 2023

BUY
$4.35 - $6.77 $17 - $27
4 New
4 $0
Q3 2022

Oct 13, 2022

SELL
$3.65 - $6.43 $3 - $6
-1 Closed
0 $0
Q1 2022

May 05, 2022

BUY
$5.05 - $7.53 $5 - $7
1 New
1 $0

Others Institutions Holding IBRX

About ImmunityBio, Inc.


  • Ticker IBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 400,304,000
  • Market Cap $1.8B
  • Description
  • ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...
More about IBRX
Track This Portfolio

Track Sjs Investment Consulting Inc. Portfolio

Follow Sjs Investment Consulting Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sjs Investment Consulting Inc., based on Form 13F filings with the SEC.

News

Stay updated on Sjs Investment Consulting Inc. with notifications on news.